Key result
TAVI improves significant mitral regurgitation in ~41% of patients, but baseline factors fail to predict response.
Why the study?
Predictors of mitral regurgitation severity improvement after transcatheter aortic valve implantation in patients with severe aortic stenosis were unknown.
Cohort (n=85)
No
Should not yet guide MR management decisions in TAVI candidates; leaves open prospective identification of responders.
BACKGROUND: Mitral regurgitation (MR) is frequently associated with severe aortic stenosis (AS). Significant MR is associated with less favorable prognosis after transcatheter aortic valve implantation (TAVI), including higher early and late mortality rate. The severity of MR is improved in about half of patients undergoing TAVI. However, the predictors of MR improvement after TAVI are unknown. We sought to investigate whether several demographic, clinical, echocardiographic and laboratory parameters and procedure characteristics are predictive of MR severity improvement after TAVI procedure. METHODS: A total of 309 consecutive patients with severe symptomatic AS underwent TAVI procedure in our center from July 1, 2015 till December 31, 2019. The 85 patients had concomitant significant (grade 2 or 3) MR. We performed logistic regression analysis of age, sex, atrial fibrillation, left ventricular ejection fraction, end diastolic diameter, end systolic diameter, left atrial diameter, left atrial area, MR etiology (functional vs. degenerative), CHA2DS2-VASc score, pre-procedure B-type natriuretic peptide (BNP) levels and type of TAVI bioprosthesis as possible predictors of post-TAVI improvement of severity of MR. RESULTS: The 35 patients have at least one grade reduction in the severity of MR in follow-up echo. None of the analyzed parameters were predicting of the MR severity improvement. CONCLUSIONS: In this small single-center cohort study, we were unable to find any feasible demographic, clinical, echocardiographic or laboratory predictors of MR improvement after TAVI. There was no correlation between etiology of MR or type of TAVI bioprosthesis used and MR improvement.
No takes yet. Share an insight, caveat, or question.
Lubovich et al. (2020) conducted a cohort in Severe symptomatic aortic stenosis with concomitant significant mitral regurgitation (n=85). Baseline clinical, echocardiographic, and laboratory parameters was evaluated on At least one grade improvement in severity of mitral regurgitation at 3 months post-TAVI. In patients with severe aortic stenosis and significant mitral regurgitation undergoing TAVI, 41.2% experienced MR improvement at 3 months, but no baseline clinical, echocardiographic, or laboratory predictors of this improvement were identified.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: